RT Journal Article
SR Electronic
T1 Trends in Clinical Validation and Usage of Food and Drug Administration (FDA)-Cleared Artificial Intelligence (AI) Algorithms for Medical Imaging
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.19.22276350
DO 10.1101/2022.06.19.22276350
A1 Khunte, Mihir
A1 Chae, Allison
A1 Wang, Richard
A1 Jain, Rishubh
A1 Sun, Yujuan
A1 Sollee, John R.
A1 Jiao, Zhicheng
A1 Bai, Harrison X.
YR 2022
UL http://medrxiv.org/content/early/2022/06/21/2022.06.19.22276350.abstract
AB Objective The objective of this study is to examine the current landscape of FDA-approved AI medical imaging devices and identify trends in clinical validation strategy.Materials and Methods We conducted a retrospective study that analyzed data extracted from the American College of Radiology (ACR) Data Science Institute AI Central database as of November 2021 to identify trends in FDA clearance of AI products related to medical imaging. Product and clinical validation information of each device was gathered from their respective public 510(k) summary or de novo request submission, depending on their type of authorization.Results Overall, the database included a total of 151 AI algorithms that were cleared by the FDA between 2008 and November 2021. Out of the 151 FDA summaries reviewed, 97 (64.2%) reported the use of clinical data to validate their device. Of these 151 summaries, 81 (53.6%) reported the total number of patient cases used during validation, with the average number of cases being 799 (SD: 1363) and the range of cases spanning from 15 to 9122. A total of 51 (33.8%) AI devices characterized their clinical data as multicenter, 3 (2.0%) as single-center, and the remaining 97 (64.2%) did not specify. The ground truth used for clinical validation was specified in 78 (51.6%) FDA summaries.Discussion and Conclusion A wide breadth of AI algorithms have been developed for medical imaging. Most of the devices’ FDA summaries mention their use of clinical data and patient cases for device validation, emphasizing their utility in real clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.